Handelsavisen
prelaunch
Companies Healthcare 2189.HK
21
2189.HK HKEX Healthcare Facilities & Services

2189.Hk

HK$0,45
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
450,0M HKD
P/E
EV / Rev
Div yield
4,12 %
Op margin
14,7 %
ROE
5,0 %
Net margin
6,9 %
Debt / equity
0,76
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.

Business. The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
5,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2189.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2189.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company maintains a market capitalization of HKD 470 million and a price-to-earnings ratio of 21.48, indicating a moderate valuation relative to its earnings. Its price-to-book ratio of 1.08 suggests that the market values the company's equity in line with its book value. The company's liquidity position is characterized by a current ratio of 1.03, which is slightly above 1, indicating a modest ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    In terms of profitability, the company reports a return on equity of 5.01% and a return on assets of 2.7%, which are below the industry median for healthcare facilities and services. This suggests that the company is not generating returns as efficiently as its peers. The operating margin, calculated as operating income divided by revenue, is 14.71%, which is a key metric for assessing operational efficiency in the healthcare sector.

    The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess the concentration of its revenue sources. However, the lack of detailed segment reporting may indicate a relatively undiversified business model. The company's revenue growth trajectory is not explicitly provided, but the absence of a clear growth pattern in the data suggests a stable or potentially stagnant revenue stream.

    The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The debt-to-equity ratio of 0.76 indicates a moderate level of leverage, which is generally acceptable for a healthcare company but may increase financial risk if interest rates rise. The company's capital expenditure of HKD -19.78 million suggests a reduction in investment in physical assets, which could be a strategic decision to preserve cash or a sign of reduced growth opportunities.

    Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The absence of recent significant events or disclosures may indicate a period of operational stability or a lack of material developments affecting the company's operations.

    Key takeaways
    • The company's valuation is moderate, with a price-to-earnings ratio of 21.48 and a price-to-book ratio of 1.08.
    • The company's return on equity and return on assets are below the industry median, indicating lower profitability.
    • The company's liquidity position is modest, with a current ratio of 1.03 and a negative net cash position after debt.
    • The company's capital expenditure is negative, suggesting a reduction in investment in physical assets.
    • The company's risk profile is characterized by medium liquidity risk and low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$0,45
    Market cap
    HK$470.0M
    Enterprise value
    HK$803.0M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    8.8x
    P / B
    1.1x
    P / Tangible book
    1.1x
    Tangible book
    HK$436.8M
    Net cash
    -HK$333.0M
    Current ratio
    1.0
    Debt / equity
    0.8
    ROA
    2.7%
    ROE
    5.0%
    Cash conversion
    415.0%
    CapEx / revenue
    -6.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin14,7 %Above median
    Net Margin6,9 %Above median
    ROE5,0 %Above median
    Capex / Rev-6,2 %Above median
    D/E0,76Below median
    Cash Conv4,15Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 2189.HK Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2189.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage